Captrust Financial Advisors Bio Affinity Technologies, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 27,885 shares of BIAF stock, worth $57,443. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,885
Previous 27,885
-0.0%
Holding current value
$57,443
Previous $56,000
7.14%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BIAF
# of Institutions
18Shares Held
400KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA172KShares$354,3070.0% of portfolio
-
Geode Capital Management, LLC Boston, MA69.6KShares$143,3760.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny23KShares$47,3120.0% of portfolio
-
Ground Swell Capital, LLC Folly Beach, SC22.9KShares$47,0990.04% of portfolio
-
State Street Corp Boston, MA17.6KShares$36,2560.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $5.62M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...